(Albany, United States) As per DelveInsight’s assessment, globally, the Pulmonary Arterial Hypertension pipeline constitutes 55+ key companies continuously working towards developing 55+ Pulmonary Arterial Hypertension treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analysis DelveInsight.

 

In the Pulmonary Arterial Hypertension Pipeline Report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, Pulmonary Arterial Hypertension NDA approvals (if any), and product development activities comprising the technology, Dyspepsia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

To explore more information on the latest breakthroughs in the Pulmonary Arterial Hypertension pipeline treatment landscape of the report, click here @ Pulmonary Arterial Hypertension Pipeline Outlook

 

Key Takeaways from the Pulmonary Arterial Hypertension Pipeline Report

• DelveInsight’s Pulmonary Arterial Hypertension Pipeline analysis depicts a robust space with 55+ active players working to develop 55+ pipeline treatment therapies.
• The leading Pulmonary Arterial Hypertension Companies in the market include Merck Sharp & Dohme, Acceleron Pharma, Liquidia Technologies, Gossamer Bio, Resverlogix, PhaseBio Pharmaceuticals, Pharmosa BioPharm, Complexa, Gmax Biopharm Australia, Mezzion, Radikal Therapeutics, Galectin Therapeutics, Altavant Sciences, Ribomic, and others
• Promising Pulmonary Arterial Hypertension Pipeline Therapies in the various stages of development include Parenteral Treprostinil, Oral Treprostinil, Epoprostenol, Treprostinil, AV-101, TPN171H, Tadalafil, LTP001, Macitentan, Selexipag, Macitentan (ACT-064992), GB002 (seralutinib), Imatinib mesylate, Sitaxentan sodium, Flolan®, and others
• On April 2023, United Therapeutics announced a study of phase 4 clinical trials for Parenteral Treprostinil and Oral Treprostinil. The primary objective of this study is to assess the effect of early and rapid treprostinil therapy for mean pulmonary artery pressure (mPAP) reduction to improve right ventricular (RV) function and reverse RV remodeling in participants with pulmonary arterial hypertension (PAH).
• On February 2023, Cereno Scientific AB announced a study of phase 2 clinical trials for CS1 Administration. This is a Phase 2, parallel group study to evaluate the safety, tolerability, PK, and exploratory efficacy of 3 doses of CS1 in the treatment of PAH using the CardioMEMS HF System to obtain repeated measurements of PAP and other hemodynamic parameters. The primary objective of the study is to obtain safety and tolerability data.
• On May 2023, Insmed Incorporated announced a study of phase 2 clinical trials for Treprostinil Palmitil. The main objective of the study is to assess the effect of treprostinil palmitil inhalation powder (TPIP) compared with placebo on pulmonary vascular resistance.
• On June 2023, Aerovate Therapeutics announced a study of phase 3 clinical trials for AV-101. IMPAHCT-FUL: Inhaled iMatinib Pulmonary Arterial Hypertension Clinical Trial – Follow Up Long Term Extension (LTE) Trial is a follow up study to establish the long-term safety of AV-101. The long-term effects of AV-101 on efficacy measures will also be assessed. Subjects who successfully complete the 24-week placebo-controlled parent trial (AV-101-002) will be offered the opportunity to continue into this LTE study. Subjects who enroll in the study will receive one of three active AV-101 doses until such time as the optimal dose has been selected in the parent study.

 

Pulmonary Arterial Hypertension Overview

Pulmonary arterial hypertension (PAH) is a rare, progressive, and life-threatening blood vessel disorder. PAH is characterized by a thickening of the pulmonary vasculature, leading to restricted blood flow and elevated blood pressure within the pulmonary vessels.

 

To explore more information on the latest breakthroughs in the Pulmonary Arterial Hypertension Pipeline treatment landscape of the report, click here @ https://www.delveinsight.com/sample-request/pulmonary-arterial-hypertension-pipeline-insight

 

Pulmonary Arterial Hypertension Emerging Drugs Profile

• Sotatercept: Acceleron Pharma
• LIQ861: Liquidia Technologies

 

Pulmonary Arterial Hypertension Pipeline Therapeutics Assessment

There are approx. 55+ key companies which are developing the therapies for Pulmonary Arterial Hypertension. The Pulmonary Arterial Hypertension companies which have their Pulmonary Arterial Hypertension drug candidates in the most advanced stage, i.e. Preregistration include, Liquidia Technologies.

 

Request a sample and discover the recent advances in Pulmonary Arterial Hypertension Ongoing Clinical Trial Analysis and Medications, click here @ https://www.delveinsight.com/sample-request/pulmonary-arterial-hypertension-pipeline-insight

 

Pulmonary Arterial Hypertension Drugs and Companies

• Parenteral Treprostinil: United Therapeutics
• Oral Treprostinil: Lung Biotechnology PBC
• Epoprostenol: Actelion
• CS1 Administration: Cereno Scientific AB
• AV-101: Aerovate Therapeutics

 

Pulmonary Arterial Hypertension Therapeutics Assessment

• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type

 

Some of the Companies in the Pulmonary Arterial Hypertension Therapeutics Market include-

Merck Sharp & Dohme, Acceleron Pharma, Liquidia Technologies, Gossamer Bio, Resverlogix, PhaseBio Pharmaceuticals, Pharmosa BioPharm, Complexa, Gmax Biopharm Australia, Mezzion, Radikal Therapeutics, Galectin Therapeutics, Altavant Sciences, Ribomic, and others

 

Dive deep into rich insights for drugs for Pulmonary Arterial Hypertension Pipeline, click here for Pulmonary Arterial Hypertension Unmet Needs and Analyst Views @ https://www.delveinsight.com/sample-request/pulmonary-arterial-hypertension-pipeline-insight

 

Scope of the Pulmonary Arterial Hypertension Pipeline Report

• Coverage- Global
• Pulmonary Arterial Hypertension Companies- Merck Sharp & Dohme, Acceleron Pharma, Liquidia Technologies, Gossamer Bio, Resverlogix, PhaseBio Pharmaceuticals, Pharmosa BioPharm, Complexa, Gmax Biopharm Australia, Mezzion, Radikal Therapeutics, Galectin Therapeutics, Altavant Sciences, Ribomic, and others
• Pulmonary Arterial Hypertension Pipeline Therapies- Parenteral Treprostinil, Oral Treprostinil, Epoprostenol, Treprostinil, AV-101, TPN171H, Tadalafil, LTP001, Macitentan, Selexipag, Macitentan (ACT-064992), GB002 (seralutinib), Imatinib mesylate, Sitaxentan sodium, Flolan®, and others
• Pulmonary Arterial Hypertension Segmentation: Product Type, Molecule Type, Route of Administration

 

Got Queries? Find out the related information on Pulmonary Arterial Hypertension Mergers and acquisitions, Licensing Activities @ https://www.delveinsight.com/sample-request/pulmonary-arterial-hypertension-pipeline-insight

 

Table of Content

1. Introduction
2. Executive Summary
3. Pulmonary Arterial Hypertension: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Pulmonary Arterial Hypertension – DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Sotatercept: Acceleron Pharma
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. GB-002: Gossamer Bio
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. Apabetalone: Resverlogix
15. Drug profiles in the detailed report…..
16. Preclinical/Discovery Stage Products
17. R107: Radikal Therapeutics
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Pulmonary Arterial Hypertension Key Companies
21. Pulmonary Arterial Hypertension Key Products
22. Pulmonary Arterial Hypertension- Unmet Needs
23. Pulmonary Arterial Hypertension- Market Drivers and Barriers
24. Pulmonary Arterial Hypertension- Future Perspectives and Conclusion
25. Pulmonary Arterial Hypertension Analyst Views
26. Appendix

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services